Novartis Reports Positive Phase III Results for Ianalumab in Immune Thrombocytopenia
I'm PortAI, I can summarize articles.
Novartis AG announced positive Phase III trial results for ianalumab in treating immune thrombocytopenia. The trial showed ianalumab plus eltrombopag extended time to treatment failure to 13 months compared to 4.7 months with placebo. 62% of patients achieved sustained platelet response at six months. Ianalumab was well tolerated, with comparable adverse events between treatment arms. Novartis plans to submit data to health authorities in 2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments